WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has entered into a definitive agreement to sell the US and UK based operations of WuXi Advanced Therapies (ATU), its cell and gene therapy unit, to Altaris, LLC, a healthcare investment firm headquartered in New York.

All other WuXi AppTec operations remain unchanged, and WuXi AppTec’s major business units – WuXi Chemistry, WuXi Biology and WuXi Testing – will continue our sharp focus on supporting innovative partners globally through the unique CRDMO enabling platform.

The transaction is expected to close in the first half of 2025, subject to customary closing conditions and receipt of required regulatory approvals.

Edward Hu, CEO of WuXi ATU, said, “Anco agreement is a positive step forward for the vital services that ATU provides. Altaris is committed to growing the ATU businesses by supporting its employees, customers and patients. At the same time, WuXi AppTec will remain laser-focused on our ‘follow-the-customer’ and ‘follow-the-molecule’ strategies, as we continue to move toward our vision that ‘every drug can be made and every disease can be treated.’”

Advisors
J.P. Morgan served as financial advisor, and Wilson Sonsini Goodrich & Rosati acted as legal advisor, to WuXi AppTec. Kirkland & Ellis LLP acted as legal counsel for Altaris.